Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17996795 | 0.91 | CA2 (0.41) | SLC22A2SLC22A1SLC22A3SLC6A4CA2 | |
| Hydrochloric Acid SCHEMBL16563090 | 0.89 | CA2 (0.40) | SLC22A2SLC22A1SLC22A3SLC6A4CA2 | |
| SCHEMBL17997006 | 0.80 | ACHE (0.41) | CA2KIF11 | |
| Hydrochloric Acid SCHEMBL16563083 | 0.80 | KIF11 (0.42) | CA2ALDH1A1TSHRTDP1KIF11 | |
| SCHEMBL17997003 | 0.79 | ALDH1A1 (0.34) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL18012043 | 0.78 | BCHE (0.41) | CA2ALDH1A1TSHRTDP1KIF11 | |
| SCHEMBL1108049 | 0.77 | SLC22A2 (0.48) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL16563077 | 0.76 | SLC22A2 (0.31) | SLC22A2SLC22A1SLC22A3SLC6A4CA2 | |
| Hydrochloric Acid SCHEMBL598047 | 0.74 | SLC22A2 (0.46) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL14596523 | 0.74 | SLC22A2 (0.46) | SLC22A2SLC22A1SLC22A3SLC6A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374230-A1 | CROSSLINKED GEL FORMULATION | ESSILOR INTERNATIONAL (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20230374230-A1 | CROSSLINKED GEL FORMULATION | ESSILOR INTERNATIONAL (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20230220274-A1 | ELECTROCHROMIC SOLUTION | ESSILOR INTERNATIONAL (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230220274-A1 | ELECTROCHROMIC SOLUTION | ESSILOR INTERNATIONAL (FR) | 2023-07-13 | — | — | US | disclosed |
| US-9841652-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-12-12 | — | — | US | disclosed |
| US-9841652-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-12-12 | — | — | US | disclosed |
| US-9823534-B2 | Electrochromic single and two-core viologens and optical articles containing them | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-11-21 | — | — | US | disclosed |
| US-9785030-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-10-10 | — | — | US | disclosed |
| US-9785030-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160282694-A1 | ELECTROCHROMIC COMPOSITION | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160231635-A1 | ELECTROCHROMIC SINGLE AND TWO-CORE VIOLOGENS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-08-11 | — | — | US | disclosed |
| US-20160231636-A1 | ELECTROCHROMIC COMPOSITION | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-08-11 | — | — | US | disclosed |
| US-20160231636-A1 | ELECTROCHROMIC COMPOSITION | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160231635-A1 | ELECTROCHROMIC SINGLE AND TWO-CORE VIOLOGENS AND OPTICAL ARTICLES CONTAINING THEM | EYA2, CRY2, EYA3 | SLC22A2 1067/4885SLC22A1 1902/4885SLC22A3 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.